Hironobu Yamashita, MS, PhD
Assistant Professor of Pathology

Penn State of College of Medicine
Hershey, PA, USA
Phone: 717-531-0003
E-mail: hyamashita@pennstatehealth.psu.edu


PhD 2000-2004 Agriculture, Nagoya University, Nagoya, Japan
MS 1998-2000 Agriculture, Nagoya University, Nagoya, Japan
BS 1994-1998 Bioscience, Fukui Prefectural University, Fukui, Japan


I am a research faculty of Pathology Department at Penn State Hershey Medical Center. After my postdoctoral training at Vanderbilt University, I worked as assistant professor at Tohoku university. Since 2014, I belonged to Department of Pathology at Penn State Hershey Medical Center, Hershey, PA. My current research interests focuses on the role transcription factors in molecular subtypes of human bladder cancer.

Research Interest

  • Protein engineering
  • Gene Regulation
  • Transcription Factor
  • Epigenetics
  • Tumor Microenvironment
  • Cancer Biology

Scientific Activities

Employment History
2014-Present Research Associate David Degraff Laboratory, Department of Pathology, Penn State of College of Medicine, Hershey, PA USA
2012-2013 Assistant Professor Department of Gynecology and Obstetrics, Tohoku University, Sendai, Japan
2010-2012 Research Fellow Robert Matusik Laboratory, Department of Urologic Surgery, Vanderbilt University, Nashville, TN USA
2004-2010 Research Fellow Vito Quaranta Laboratory, Department of Cancer Biology, Vanderbilt University, Nashville, TN USA
Honors and Awards
  • Nov. 2017- Travel Award, Biomedical Big Data Resources and Analysis Tools, Workshop at Georgetown University, Washington DC USA
  • Nov. 2014 - Travel Award, SBUR (Society For Basic Urologic Research) Fall, Sympodium, Dallas, TX USA
  • Sep. 2010 - Travel Award, the endocrine society for the sixth international, symposium on hormonal oncogenesis, Tokyo, Japan
  • Jul. 2002 - Chairs Fund of Gordon Research Conferences (Basement Membrane), Holderness, NH USA


  1. Nandana S, Tripathi M, Duan P, Chu CY, Mishra R, Liu C, Jin R, Yamashita H, Zayzafoon M, Bhowmick NA, Zhau HE, Matusik RJ, Chung LW. Bone metastasis of prostate cancer can be therapeutically targeted at the TBX2-WNT signaling axis. Cancer Res. (2017). doi: 10.1158/0008-5472.CAN-16-0497.
  2. Yamashita H, Amponsa VO, Warrick JI, Zheng Z, Clark PE, Raman JD, Wu XR, Mendelsohn C, Degraff DJ. On a FOX hunt: functions of FOX transcriptional regulators in bladder cancer. Nat Rev Urol. 14(2):98-106 (2017). Review. doi: 10.1038/nrurol.2016.239.
  3. Warrick JI, Walter V, Yamashita H, Chung E, Shuman L, Amponsa VO, Zheng Z, Chan W, Whitcomb TL, Yue F, Iyyanki T, Kawasawa YI, Kaag M, Guo W, Raman JD, Park JS, Degraff DJ. FOXA1, GATA3 and PPARG cooperate to drive luminal subtype in bladder cancer: A molecular analysis of established human cell lines. Sci Rep. 6:38531 (2016). doi: 10.1038/srep38531.
  4. Reddy OL, Cates JM, Gellert LL, Crist HS, Yang Z, Yamashita H, Taylor JA, Smith JA, Chang SS, Cookson MS, You C, Barocas DA, Grabowska MM, Ye F, Wu XR, Yi Y, Matusik RJ, Kaestner KH, Clark PE, DeGraff DJ. Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer. Am J Pathol 185(5):1385-95 (2015).
  5. Jin R, Yamashita H, Yu X, Wang J, Franco OE, Wang Y, Hayward SW, MatusikRJ. Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression. Oncogene. 34(28):3700-10 (2015).
  6. Grabowska MM, Elliott AD, DeGraff DJ, Anderson PD, Anumanthan G, Yamashita H, Sun Q, Friedman DB, Hachey DL, Yu X, Sheehan JH, Ahn JM, Raj GV, Piston DW, Gronostajski RM, Matusik RJ. NFI transcription factors interact with FOXA1 to regulate prostate-specific gene expression. Mol Endocrinol. 28(6):949-64 (2014).
  7. DeGraff DJ, Clark PE, Cates JM, Yamashita H, Robinson VL, Yu X, Smolkin ME, Chang SS, Cookson MS, Herrick MK, Shariat SF, Steinberg GD, Frierson HF, Wu XR, Theodorescu D, Matusik RJ. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. PLoS One. 7:e36669 (2012).
  8. Takahashi K, Mernaugh R, Friedman D, Weller R, Tsuboi N, Yamashita H, Quaranta V, Takahashi T. Thrombospondin-1 acts as a ligand for CD148 tyrosine phosphatase. Proc Natl Acad Sci U S A. 109:1985-1990 (2012).
  9. Tripathi M, Potdar AA, Yamashita H, Weidow B, Cummings PT, Kirchhofer D, Quaranta V. Laminin-332 cleavage by matriptase alters motility parameters of prostate cancer cells. Prostate. 71:184-196 (2011).
  10. Yamashita H, Tripathi M, Jourquin J, Kam Y, Liu S, Weidow B, Quaranta V. Lysophosphatidic acid upregulates laminin-332 expression during A431 cell colony dispersal. Journal of Oncology. pii: 107075 (2010).
  11. Ocak S, Yamashita H, Udyavar AR, Miller AN, Gonzalez AL, Zou Y, Jiang A, Yi Y, Shyr Y, Estrada L, Quaranta V, Massion PP. DNA copy number aberrations in small-cell lung cancer reveal activation of the focal adhesion pathway. Oncogene. 29:6331-6342 (2010).
  12. Yamashita H, Shang M, Tripathi M, Liu S, Weidow B, Quaranta V. Epitope mapping of function-blocking monoclonal antibody CM6 suggests a "weak" integrin binding site on the laminin-332 LG2 domain. J Cell Physiol. 223: 541-548 (2010).
  13. Yamashita H, Tripathi M, Harris M.P., Ronca F, Liu S, Weidow B, Zent R, Quaranta V. A recombinant fragment of laminin-332 directs integrin α3β1- dependent cell binding, spreading, and migration. Biomaterials. 31:5110-5121 (2010).
  14. Liu, S, Yamashita H, Weidow B, Weaver A, Quaranta V. Laminin-332-β1integrin interactions negatively regulate invadopodia. J Cell Physiol. 223: 134-142 (2010).
  15. Tripathi M, Nandana S, Yamashita H, Ganesan R, Kirchhofer D, Quaranta V*. Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression. J Biol Chem. 283: 30576-30584 (2008).
  16. Yamashita H, Goto C, Tajima R, A. Koparal T, Kobori M, Ohki Y, Shitara K, Narita R, Toriyama K, Torii S, Niimi T*, Kitagawa Y. Cryptic fragment alpha4 LG-4-5 derived from laminin alpha4 chain inhibits de novo adipogenesis by modulating the effect of fibroblast growth factor-2. Dev Growth Differ. 50: 97-107 (2008).
  17. Yamashita H, Beck K, Kitagawa Y*. Heparin binds to the laminin alpha4 chain LG4 domain at a site different from that found for other laminins. J Mol Biol. 335:1145-1149 (2004).
  18. Narita R#, Yamashita H#, Goto A#, Imai H#, Ichihara S, Mori H, Kitagawa Y*. Syndecan-dependent binding of Drosophila hemocytes to laminin alpha3/5 chain LG4-5 modules: potential role in sessile hemocyte islets formation. FEBS Lett. 576:127-132 (2004). #Equal contribution to this work.
  19. Yamashita H, Goto A, Kadowaki T, Kitagawa Y*. Mammalian and Drosophila cells adhere to the laminin alpha4 LG4 domain through syndecans, but not glypicans. Biochem J. 382:933-943 (2004).
  20. Suzuki N, Ichikawa N, Kasai S, Yamada M, Nishi N, Morioka H, Yamashita H, Kitagawa Y, Utani A, Hoffman MP, Nomizu M. Syndecan binding sites in the laminin alpha1 chain G domain. Biochemistry. 42:12625-12633 (2003).
  21. Okazaki I, Suzuki N, Nishi N, Utani A, Matsuura H, Shinkai H, Yamashita H, Kitagawa Y, Nomizu M. Identification of biologically active sequences in the laminin alpha 4 chain G domain. J Biol Chem. 277: 37070-37078 (2002).
  22. Yamaguchi H#, Yamashita H#, Mori H, Okazaki I, Nomizu M, Beck K, Kitagawa Y. High and low affinity heparin-binding sites in the G domain of the mouse laminin alpha 4 chain. J Biol Chem. 275:29458-29465 (2000). #Equal contribution to this work.

Pathology and Therapeutics Flyer